1
|
Orwig T, Sutaria S, Wang Z, Howard-Wilson S, Dunlap D, Lilly CM, Buchholz B, McManus DD, Hafer N. Sampling of healthcare professionals' perspective on point-of-care technologies from 2019-2021: A survey of benefits, concerns, and development. PLoS One 2024; 19:e0299516. [PMID: 38457401 PMCID: PMC10923439 DOI: 10.1371/journal.pone.0299516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Accepted: 02/09/2024] [Indexed: 03/10/2024] Open
Abstract
Point-of-care technology (POCT) plays a vital role in modern healthcare by providing a fast diagnosis, improving patient management, and extending healthcare access to remote and resource-limited areas. The objective of this study was to understand how healthcare professionals in the United States perceived POCTs during 2019-2021 to assess the decision-making process of implementing these newer technologies into everyday practice. A 5-point Likert scale survey was sent to respondents to evaluate their perceptions of benefits, concerns, characteristics, and development of point-of-care technologies. The 2021 survey was distributed November 1st, 2021- February 15th, 2022, with a total of 168 independent survey responses received. Of the respondents, 59% identified as male, 73% were white, and 48% have been in practice for over 20 years. The results showed that most agreed that POCTs improve patient management (94%) and improve clinician confidence in decision making (92%). Healthcare professionals were most concerned with potentially not being reimbursed for the cost of the POCT (37%). When asked to rank the top 3 important characteristics of POCT, respondents chose accuracy, ease of use, and availability. It is important to note this survey was conducted during the COVID-19 pandemic. To achieve an even greater representation of healthcare professionals' point of view on POCTs, further work to obtain responses from a larger, more diverse population of providers is needed.
Collapse
Affiliation(s)
- Taylor Orwig
- Department of Medicine, UMass Chan Medical School, Worcester, MA, United States of America
| | - Shiv Sutaria
- Department of Medicine, UMass Chan Medical School, Worcester, MA, United States of America
| | - Ziyue Wang
- Department of Medicine, UMass Chan Medical School, Worcester, MA, United States of America
| | - Sakeina Howard-Wilson
- Department of Medicine, UMass Chan Medical School, Worcester, MA, United States of America
| | - Denise Dunlap
- Manning School of Business, UMass Lowell, Lowell, MA, United States of America
| | - Craig M. Lilly
- Department of Medicine, UMass Chan Medical School, Worcester, MA, United States of America
- Department of Anesthesiology and Perioperative Medicine, UMass Chan Medical School, Worcester, Massachusetts, United States of America
- Department of Surgery, UMass Chan Medical School, Worcester, Massachusetts, United States of America
| | - Bryan Buchholz
- Department of Biomedical Engineering, UMass Lowell, Lowell, MA, United States of America
| | - David D. McManus
- Department of Medicine, UMass Chan Medical School, Worcester, MA, United States of America
- Department of Population and Quantitative Health Sciences, UMass Chan Medical School, Worcester, MA, United States of America
| | - Nathaniel Hafer
- UMass Center for Clinical and Translational Science, UMass Chan Medical School, Worcester, MA, United States of America
- Program in Molecular Medicine, UMass Chan Medical School, Worcester, MA, United States of America
| |
Collapse
|
2
|
Colom G, Hernandez-Albors A, Barallat J, Galan A, Bayes-Genis A, Salvador JP, Marco MP. A multiplexed immunochemical microarray for the determination of cardiovascular disease biomarkers. Mikrochim Acta 2023; 191:53. [PMID: 38151630 PMCID: PMC10752916 DOI: 10.1007/s00604-023-06119-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 11/23/2023] [Indexed: 12/29/2023]
Abstract
A fluorescence antibody microarray has been developed for the determination of relevant cardiovascular disease biomarkers for the analysis of human plasma samples. Recording characteristic protein molecular fingerprints to assess individual's states of health could allow diagnosis to go beyond the simple identification of the disease, providing information on its stage or prognosis. Precisely, cardiovascular diseases (CVDs) are complex disorders which involve different degenerative processes encompassing a collection of biomarkers related to disease progression or stage. The novel approach that we propose is a fluorescent microarray chip has been developed accomplishing simultaneous determination of the most significant cardiac biomarkers in plasma aiming to determine the CVD status stage of the patient. As proof of concept, we have chosen five relevant biomarkers, C-reactive protein (CRP) as biomarker of inflammation, cystatin C (CysC) as biomarker of renal failure that is directly related with heart failure, cardiac troponin I (cTnI) as already established biomarker for cardiac damage, heart fatty acid binding protein as biomarker of ischemia (H-FABP), and finally, NT-proBNP (N-terminal pro-brain natriuretic peptide), a well-established heart failure biomarker. After the optimization of the multiplexed microarray, the assay allowed the simultaneous determination of 5 biomarkers in a buffer solution reaching LODs of 15 ± 5, 3 ± 1, 24 ± 3, 25 ± 3, and 3 ± 1 ng mL-1, for CRP, CysC, H-FABP, cTnI, and NT-proBNP, respectively. After solving the matrix effect, and demonstrating the accuracy for each biomarker, the chip was able to determine 24 samples per microarray chip. Then, the microarray has been used on a small pilot clinical study with 29 plasma samples from clinical patients which suffered different CVD and other related disorders. Results show the superior capability of the chip to provide clinical information related to the disease in terms of turnaround time (1 h 30 min total assay and measurement) and amount of information delivered in respect to reference technologies used in hospital laboratories (clinical analyzers). Despite the failure to detect c-TnI at the reported threshold, the microarray technology could be a powerful approach to diagnose the cardiovascular disease at early stage, monitor its progress, and eventually providing information about an eminent potential risk of suffering a myocardial infarction. The microarray chip here reported could be the starting point for achieving powerful multiplexed diagnostic technologies for the diagnosis of CVDs or any other pathology for which biomarkers have been identified at different stages of the disease.
Collapse
Affiliation(s)
- Gloria Colom
- Nanobiotechnology for Diagnostics (Nb4D), Department of Chemical and Biomolecular Nanotechnology, Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Av. Monforte de Lemos, 3-5, 28029, Madrid, Spain
| | - Alejandro Hernandez-Albors
- Nanobiotechnology for Diagnostics (Nb4D), Department of Chemical and Biomolecular Nanotechnology, Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Av. Monforte de Lemos, 3-5, 28029, Madrid, Spain
| | - Jaume Barallat
- Biochemistry Department, Metropolitan North Clinical Laboratory (LCMN), Germans Trias i Pujol Universitary Hospital, Ctra. de Canyet, s/n, Badalona, Barcelona, Spain
| | - Amparo Galan
- Institut del Cor Germans Trias I Pujol, Ctra. de Canyet, 1-3, 08916, Badalona, Spain
| | - Antoni Bayes-Genis
- Institut del Cor Germans Trias I Pujol, Ctra. de Canyet, 1-3, 08916, Badalona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Av. Monforte de Lemos, 3-5, 28029, Madrid, Spain
| | - Juan-Pablo Salvador
- Nanobiotechnology for Diagnostics (Nb4D), Department of Chemical and Biomolecular Nanotechnology, Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Av. Monforte de Lemos, 3-5, 28029, Madrid, Spain.
| | - Maria-Pilar Marco
- Nanobiotechnology for Diagnostics (Nb4D), Department of Chemical and Biomolecular Nanotechnology, Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Av. Monforte de Lemos, 3-5, 28029, Madrid, Spain
| |
Collapse
|
3
|
Larcher R, Lottelier M, Badiou S, Dupuy AM, Bargnoux AS, Cristol JP. Analytical Performances of the Novel i-STAT Alinity Point-of-Care Analyzer. Diagnostics (Basel) 2023; 13:diagnostics13020297. [PMID: 36673107 PMCID: PMC9857650 DOI: 10.3390/diagnostics13020297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 12/21/2022] [Accepted: 01/08/2023] [Indexed: 01/15/2023] Open
Abstract
Many Point-of-Care devices have been released over the past decade. However, data regarding their analytical performances in real-world situations remains scarce. Herein, we aimed to assess the analytical performances of the i-STAT Alinity system. We conducted an analytical performances study with the i-STAT Alinity device using cartridges CG4+ (pH, Pco2, Po2, lactate, bicarbonate and base excess); CHEM8+ (Na, K, Cl, ionized Ca, urea, creatinine, glucose, hematocrit and hemoglobin) and PT/INR (prothrombin time and international normalized ratio). We assessed the imprecision and compared the results to those obtained on existing instruments in the central laboratory. We found that the within-lab coefficients of variation (CV) were very low (<2%) or low (2−5%), except for creatinine and PT (CV = 5.2% and CV = 6.3%, respectively). For almost all the parameters, the results were strongly (R2 = 90−95%) or very strongly (R2 > 95%) correlated with those of the existing laboratory instruments, and the biases were very low (<2%) or low (2−5%). However, correlations of the PT and INR measurements with existing instruments were lower (R2 = 86.0% and 89.7%), and biases in the Po2 (7.9%), creatinine (5.4%) and PT (−6.6%) measurements were higher. The i-STAT Alinity appeared as a convenient device for measurements of numerous parameters. However, clinicians should interpret Po2, creatinine and PT results with caution.
Collapse
Affiliation(s)
- Romaric Larcher
- Biochemistry and Hormonology Department, Montpellier University Hospital, PhyMedExp (Physiology and Experimental Medicine), INSERM (French Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research), University of Montpellier, 34000 Montpellier, France
- Infectious and Tropical Diseases Department, Nimes University Hospital, 30000 Nimes, France
- Correspondence: ; Tel.: +33-466-68-41-49
| | - Maxence Lottelier
- Biochemistry and Hormonology Department, Montpellier University Hospital, 34000 Montpellier, France
| | - Stephanie Badiou
- Biochemistry and Hormonology Department, Montpellier University Hospital, PhyMedExp (Physiology and Experimental Medicine), INSERM (French Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research), University of Montpellier, 34000 Montpellier, France
| | - Anne-Marie Dupuy
- Biochemistry and Hormonology Department, Montpellier University Hospital, 34000 Montpellier, France
| | - Anne-Sophie Bargnoux
- Biochemistry and Hormonology Department, Montpellier University Hospital, PhyMedExp (Physiology and Experimental Medicine), INSERM (French Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research), University of Montpellier, 34000 Montpellier, France
| | - Jean-Paul Cristol
- Biochemistry and Hormonology Department, Montpellier University Hospital, PhyMedExp (Physiology and Experimental Medicine), INSERM (French Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research), University of Montpellier, 34000 Montpellier, France
| |
Collapse
|
4
|
Teebagy S, Wang Z, Dunlap D, Saleeba C, DiMezza D, Crain J, Lilly CM, Buchholz B, McManus DD, Hafer N. Understanding Healthcare Professionals' Perspectives on Point-of-Care Testing. Diagnostics (Basel) 2022; 12:533. [PMID: 35204622 PMCID: PMC8870944 DOI: 10.3390/diagnostics12020533] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/09/2022] [Accepted: 02/16/2022] [Indexed: 12/05/2022] Open
Abstract
Point-of-care testing (POCT) is an emerging technology that provides crucial assistance in delivering healthcare. The COVID-19 pandemic led to the accelerated importance of POCT technology due to its in-home accessibility. While POCT use and implementation has increased, little research has been published about how healthcare professionals perceive these technologies. The objective of our study was to examine the current perspectives of healthcare professionals towards POCT. We surveyed healthcare professionals to quantify perceptions of POCT usage, adoption, benefits, and concerns between October 2020 and November 2020. Questions regarding POCT perception were assessed on a 5-point Likert Scale. We received a total of 287 survey responses. Of the respondents, 53.7% were male, 66.6% were white, and 30.7% have been in practice for over 20 years. We found that the most supported benefit was POCTs ability to improve patient management (92%) and that the most supported concern was that POCTs lead to over-testing (30%). This study provides a better understanding of healthcare workers' perspectives on POCT. To improve patient outcomes through the usage of POCT, greater research is needed to assess the needs and concerns of industry and healthcare stakeholders.
Collapse
Affiliation(s)
- Sean Teebagy
- Department of Medicine, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA; (S.T.); (Z.W.); (C.S.); (D.D.); (C.M.L.); (D.D.M.)
| | - Ziyue Wang
- Department of Medicine, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA; (S.T.); (Z.W.); (C.S.); (D.D.); (C.M.L.); (D.D.M.)
| | - Denise Dunlap
- Manning School of Business, UMass Lowell, 220 Pawtucket St., Lowell, MA 01854, USA;
| | - Connor Saleeba
- Department of Medicine, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA; (S.T.); (Z.W.); (C.S.); (D.D.); (C.M.L.); (D.D.M.)
| | - Danielle DiMezza
- Department of Medicine, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA; (S.T.); (Z.W.); (C.S.); (D.D.); (C.M.L.); (D.D.M.)
| | - JoAnn Crain
- Clinical Laboratory Operations, UMass Memorial Health, 55 Lake Ave. N, Worcester, MA 01655, USA;
| | - Craig M. Lilly
- Department of Medicine, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA; (S.T.); (Z.W.); (C.S.); (D.D.); (C.M.L.); (D.D.M.)
- Department of Anesthesiology and Perioperative Medicine, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA
- Department of Surgery, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA
| | - Bryan Buchholz
- Department of Biomedical Engineering, UMass Lowell, 220 Pawtucket St., Lowell, MA 01854, USA;
| | - David D. McManus
- Department of Medicine, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA; (S.T.); (Z.W.); (C.S.); (D.D.); (C.M.L.); (D.D.M.)
- Department of Population and Quantitative Health Sciences, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA
| | - Nathaniel Hafer
- UMass Center for Clinical and Translational Science, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA
- Program in Molecular Medicine, UMass Chan Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA
| |
Collapse
|
5
|
Belsare S, Tseng D, Ozcan A, Coté G. Monitoring gestational diabetes at the point-of-care via dual glycated albumin lateral flow assays in conjunction with a handheld reader. Analyst 2022; 147:5518-5527. [DOI: 10.1039/d2an01238c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
A dual assay cartridge was developed and used in conjunction with a handheld reader for sensing % glycated albumin to monitor gestational diabetes at home.
Collapse
Affiliation(s)
- Sayali Belsare
- Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA
| | - Derek Tseng
- Electrical and Computer Engineering Department, University of California, Los Angeles, CA, USA
| | - Aydogan Ozcan
- Electrical and Computer Engineering Department, University of California, Los Angeles, CA, USA
- Bioengineering Department, University of California, Los Angeles, CA, USA
| | - Gerard Coté
- Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA
- Texas Engineering Experiment Station Centre for Remote Health Technologies and Systems, College Station, TX, USA
| |
Collapse
|
6
|
Dunlap DR, Santos RS, Lilly CM, Teebagy S, Hafer NS, Buchholz BO, McManus DD. COVID-19: a gray swan's impact on the adoption of novel medical technologies. HUMANITIES & SOCIAL SCIENCES COMMUNICATIONS 2022; 9:232. [PMID: 35821762 PMCID: PMC9263801 DOI: 10.1057/s41599-022-01247-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 06/23/2022] [Indexed: 05/16/2023]
Abstract
The COVID-19 pandemic offers a unique context and opportunity to investigate changes in healthcare professional perceptions towards the adoption of novel medical technologies, such as point-of-care technologies (POCTs). POCTs are a nascent technology that has experienced rapid growth as a result of COVID-19 due to their ability to increase healthcare accessibility via near-patient delivery, including at-home. We surveyed healthcare professionals before and during COVID-19 to explore whether the pandemic altered their perceptions about the usefulness of POCTs. Our network analysis method provided a structure for understanding this changing phenomenon. We uncovered that POCTs are not only useful for diagnosing COVID-19, but healthcare professionals also perceive them as increasingly important for diagnosing other diseases, such as cardiovascular, endocrine, respiratory, and metabolic diseases. Healthcare professionals also viewed POCTs as facilitating the humanization of epidemiology by improving disease management/monitoring and strengthening the clinician-patient relationship. As the accuracy and integration of these technologies into mainstream healthcare delivery improves, hurdles to their adoption dissipate, thereby encouraging healthcare professionals to rely upon them more frequently to diagnose, manage, and monitor diseases. The technological advances made in POCTs during COVID-19, combined with shifting positive perceptions of their utility by healthcare professionals, may better prepare us for the next pandemic.
Collapse
Affiliation(s)
| | | | - Craig M. Lilly
- University of Massachusetts Chan Medical School, Worcester, MA USA
| | - Sean Teebagy
- University of Massachusetts Chan Medical School, Worcester, MA USA
| | | | | | - David D. McManus
- University of Massachusetts Chan Medical School, Worcester, MA USA
| |
Collapse
|